4SC AG (FSCGF.PK), a biotech firm focused on discovery and development, Tuesday said its first quarter loss narrowed, backed on by higher revenues. The firm attributed the revenue increase mainly to the cooperation agreements signed with BioNTech AG and LEO Pharman A/S.
For the first quarter, the firm reported loss of 2.6 million euros, compared with the loss of 3.6 million euros during the corresponding quarter last year. On a per share basis, the loss for the quarter was euro 0.05 per share compared with loss of euro 0.09 per share last year. The company said there has been no tax for the period.
Revenues for the three-month period rose up to 0.79 million euros, from the prior year's figure of 0.36 million euros.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.